Actinium Pharmaceuticals Inc ATNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.89
- Day Range
- $0.89–0.93
- 52-Week Range
- $0.88–1.89
- Bid/Ask
- $0.90 / $0.98
- Shares Outstanding
- 31.37M
- Market Cap
- $28.92M
- Volume/Avg
- 56,470 / 162,388
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 319.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.actiniumpharma.com
Valuation
|
Metric
|
ATNM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.55 |
Price/Sales | 319.66 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATNM
|
|---|---|
Quick Ratio | 5.73 |
Current Ratio | 5.89 |
Interest Coverage | — |
Quick Ratio
ATNM
Profitability
|
Metric
|
ATNM
|
|---|---|
Return on Assets (Normalized) | −40.60% |
Return on Equity (Normalized) | −168.62% |
Return on Invested Capital (Normalized) | −166.33% |
Return on Assets
ATNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#!MDF<P | LOCK|@#nX^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wgsJv?g | LOCK|Dc@h | $71B | |||
| argenx SE ADR
ARGX
| LOCK|dvhM&@@ | LOCK|x%d | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|sDr?&^P | LOCK|hB# | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|pHR@Zyw | LOCK|x%&t$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<$h$l$g | LOCK|!h#!G | $26B | |||
| Moderna Inc
MRNA
| LOCK|NSjHYf | LOCK|$!z | $25B | |||
| Incyte Corp
INCY
| LOCK|L!h%dn | LOCK|Kt< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qt#mpqH | LOCK|gc | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|C$?BHCn | LOCK|lH | $16B |
United States